Global PD-L1 Testing and Therapeutics Market - 2025-2033
Global PD-L1 Testing and Therapeutics Market reached US$ 52.05 billion in 2023 and is expected to reach US$ 159.84 billion by 2033, growing with a CAGR of 11.60% during the forecast period 2026-2033.
The Global PD-L1 Testing and Therapeutics Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Global PD-L1 Testing and Therapeutics Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Product Type
Both primary and secondary data sources have been used in the global Global PD-L1 Testing and Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Global PD-L1 Testing and Therapeutics Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Global PD-L1 Testing and Therapeutics Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Product Type
- PD-L1 Therapeutics*
- PD-L1 Testing (Diagnostics)
- Immunohistochemistry (IHC)*
- Next-Generation Sequencing (NGS)
- Non-Small Cell Lung Cancer*
- Triple-Negative Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Esophageal Squamous Cell Carcinoma
- Others
- Hospitals*
- Cancer Specialty Clinics
- Diagnostic Laboratories
- Others
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Global PD-L1 Testing and Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY PRODUCT TYPE
4.1. Snippet by Testing Type
4.2. Snippet by Indication
5. SNIPPET BY END USER
5.1. Snippet by Region
6. DYNAMICS
6.1. Impacting Factors
6.1.1. Drivers
6.1.1.1. Rising Adoption of Immuno-Oncology and Precision Medicine
6.1.1.2. Expansion of Approved Indications for PD-1/PD-L1 Inhibitors
6.1.2. Restraints
6.1.2.1. High Cost of Testing and Therapeutics
6.1.2.2. Reimbursement and Access Barriers in Some Markets
6.1.3. Opportunity
6.1.3.1. Development of Multiplex and NGS-based biomarker panels
6.1.3.2. Growth in Bispecific and Multi-target Immunotherapies
6.1.4. Impact Analysis
7. GLOBAL PD-L1 TESTING AND THERAPEUTICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
7.1. Market Leaders and Pioneers
7.1.1. Emerging Pioneers and Prominent Players
7.1.2. Established leaders with largest largest-selling Brand
7.1.3. Market leaders with established products & Services
7.2. Product Developments and Breakthroughs
7.3. Regulatory and Reimbursement Landscape
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. South America
7.3.5. Middle East & Africa
7.4. Porter’s Five Force Analysis
7.5. Supply Chain Analysis
7.6. Patent Analysis
7.7. SWOT Analysis
7.8. Unmet Needs and Gaps
7.9. Recommended Strategies for Market Entry and Expansion
7.10. Pricing Analysis and Price Dynamics
8. GLOBAL PD-L1 TESTING AND THERAPEUTICS MARKET: BY PRODUCT TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.1.2. Market Attractiveness Index, By Product Type
8.2. PD-L1 Therapeutics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. PD-L1 Testing (Diagnostics)
9. GLOBAL PD-L1 TESTING AND THERAPEUTICS MARKET: BY TESTING TYPE
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
9.1.2. Market Attractiveness Index, By Testing Type
9.2. Immunohistochemistry (IHC)*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Next-Generation Sequencing (NGS)
10. GLOBAL PD-L1 TESTING AND THERAPEUTICS MARKET: BY INDICATION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.1.2. Market Attractiveness Index, By Indication
10.2. Non-Small Cell Lung Cancer*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Triple-Negative Breast Cancer
10.4. Head and Neck Squamous Cell Carcinoma
10.5. Esophageal Squamous Cell Carcinoma
10.6. Others
11. GLOBAL PD-L1 TESTING AND THERAPEUTICS MARKET: BY END USER
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.1.2. Market Attractiveness Index, By End User
11.2. Hospitals*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Cancer Specialty Clinics
11.4. Diagnostic Laboratories
11.5. Others
12. GLOBAL PD-L1 TESTING AND THERAPEUTICS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
13. INTRODUCTION
13.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.1. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. U.K.
13.3.7.3. France
13.3.7.4. Spain
13.3.7.5. Italy
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. South Korea
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
14. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
15. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
15.1. Market Share Analysis and Positioning Matrix
15.2. Strategic Partnerships, Mergers & Acquisitions
15.3. Key Developments in Product Portfolios and Innovations
15.4. Company Benchmarking
16. COMPANY PROFILES
16.1. Agilent Technologies (Dako)*
16.1.1. Company Overview
16.1.1.1. Product Portfolio
16.1.1.2. Product Description
16.1.1.3. Product Key Performance Indicators (KPIs)
16.1.1.4. Historic and Forecasted Product Sales
16.1.1.5. Product Sales Volume
16.1.2. Financial Overview
16.1.2.1. Company Revenue
16.1.2.2. Geographical Revenue Shares
16.1.2.3. Revenue Forecasts
16.1.3. Key Developments
16.1.3.1. Mergers & Acquisitions
16.1.3.2. Key Product Development Activities
16.1.3.3. Regulatory Approvals, etc.
16.1.3.4. SWOT Analysis
16.2. Roche/Ventana Medical Systems
16.3. Merck & Co., Inc.
16.4. Bristol Myers Squibb
16.5. AstraZeneca
16.6. Regeneron Pharmaceuticals
16.7. Summit Therapeutics Inc (LIST NOT EXHAUSTIVE)
17. ASSUMPTIONS AND RESEARCH METHODOLOGY
17.1. Data Collection Methods
17.2. Data Triangulation
17.3. Forecasting Techniques
17.4. Data Verification and Validation
18. APPENDIX
18.1. About Us and Services
18.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY PRODUCT TYPE
4.1. Snippet by Testing Type
4.2. Snippet by Indication
5. SNIPPET BY END USER
5.1. Snippet by Region
6. DYNAMICS
6.1. Impacting Factors
6.1.1. Drivers
6.1.1.1. Rising Adoption of Immuno-Oncology and Precision Medicine
6.1.1.2. Expansion of Approved Indications for PD-1/PD-L1 Inhibitors
6.1.2. Restraints
6.1.2.1. High Cost of Testing and Therapeutics
6.1.2.2. Reimbursement and Access Barriers in Some Markets
6.1.3. Opportunity
6.1.3.1. Development of Multiplex and NGS-based biomarker panels
6.1.3.2. Growth in Bispecific and Multi-target Immunotherapies
6.1.4. Impact Analysis
7. GLOBAL PD-L1 TESTING AND THERAPEUTICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
7.1. Market Leaders and Pioneers
7.1.1. Emerging Pioneers and Prominent Players
7.1.2. Established leaders with largest largest-selling Brand
7.1.3. Market leaders with established products & Services
7.2. Product Developments and Breakthroughs
7.3. Regulatory and Reimbursement Landscape
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. South America
7.3.5. Middle East & Africa
7.4. Porter’s Five Force Analysis
7.5. Supply Chain Analysis
7.6. Patent Analysis
7.7. SWOT Analysis
7.8. Unmet Needs and Gaps
7.9. Recommended Strategies for Market Entry and Expansion
7.10. Pricing Analysis and Price Dynamics
8. GLOBAL PD-L1 TESTING AND THERAPEUTICS MARKET: BY PRODUCT TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.1.2. Market Attractiveness Index, By Product Type
8.2. PD-L1 Therapeutics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. PD-L1 Testing (Diagnostics)
9. GLOBAL PD-L1 TESTING AND THERAPEUTICS MARKET: BY TESTING TYPE
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
9.1.2. Market Attractiveness Index, By Testing Type
9.2. Immunohistochemistry (IHC)*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Next-Generation Sequencing (NGS)
10. GLOBAL PD-L1 TESTING AND THERAPEUTICS MARKET: BY INDICATION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.1.2. Market Attractiveness Index, By Indication
10.2. Non-Small Cell Lung Cancer*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Triple-Negative Breast Cancer
10.4. Head and Neck Squamous Cell Carcinoma
10.5. Esophageal Squamous Cell Carcinoma
10.6. Others
11. GLOBAL PD-L1 TESTING AND THERAPEUTICS MARKET: BY END USER
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.1.2. Market Attractiveness Index, By End User
11.2. Hospitals*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Cancer Specialty Clinics
11.4. Diagnostic Laboratories
11.5. Others
12. GLOBAL PD-L1 TESTING AND THERAPEUTICS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
13. INTRODUCTION
13.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.1. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. U.K.
13.3.7.3. France
13.3.7.4. Spain
13.3.7.5. Italy
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. South Korea
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
14. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
15. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
15.1. Market Share Analysis and Positioning Matrix
15.2. Strategic Partnerships, Mergers & Acquisitions
15.3. Key Developments in Product Portfolios and Innovations
15.4. Company Benchmarking
16. COMPANY PROFILES
16.1. Agilent Technologies (Dako)*
16.1.1. Company Overview
16.1.1.1. Product Portfolio
16.1.1.2. Product Description
16.1.1.3. Product Key Performance Indicators (KPIs)
16.1.1.4. Historic and Forecasted Product Sales
16.1.1.5. Product Sales Volume
16.1.2. Financial Overview
16.1.2.1. Company Revenue
16.1.2.2. Geographical Revenue Shares
16.1.2.3. Revenue Forecasts
16.1.3. Key Developments
16.1.3.1. Mergers & Acquisitions
16.1.3.2. Key Product Development Activities
16.1.3.3. Regulatory Approvals, etc.
16.1.3.4. SWOT Analysis
16.2. Roche/Ventana Medical Systems
16.3. Merck & Co., Inc.
16.4. Bristol Myers Squibb
16.5. AstraZeneca
16.6. Regeneron Pharmaceuticals
16.7. Summit Therapeutics Inc (LIST NOT EXHAUSTIVE)
17. ASSUMPTIONS AND RESEARCH METHODOLOGY
17.1. Data Collection Methods
17.2. Data Triangulation
17.3. Forecasting Techniques
17.4. Data Verification and Validation
18. APPENDIX
18.1. About Us and Services
18.2. Contact Us
